These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ, VANISH Investigators. JAMA; 2016 Aug 02; 316(5):509-18. PubMed ID: 27483065 [Abstract] [Full Text] [Related]
10. Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock. Wu JY, Stollings JL, Wheeler AP, Semler MW, Rice TW. Ann Pharmacother; 2017 Jan 28; 51(1):13-20. PubMed ID: 27630192 [Abstract] [Full Text] [Related]
11. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Russell JA, Vincent JL, Kjølbye AL, Olsson H, Blemings A, Spapen H, Carl P, Laterre PF, Grundemar L. Crit Care; 2017 Aug 15; 21(1):213. PubMed ID: 28807037 [Abstract] [Full Text] [Related]
15. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Bachetoni A, D'Alessandro M, Van Aken H, Pietropaoli P, Westphal M. Crit Care; 2009 Aug 15; 13(4):R130. PubMed ID: 19664253 [Abstract] [Full Text] [Related]